Shares of Agios Pharmaceuticals Inc. (AGIO) have retreated approximately 43% from their 52-week high of $62.58, reported last November, and trade near the $35 level.
The company's flagship drug, PYRUKYND, has demonstrated strong year-over-year sales growth since its initial approval in February 2022. The drug is currently indicated for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.